09/10/2026
Lung cancer is still the deadliest cancer in the U.S. Our co-founder and co-director, Dr. Bryant Lin, has spent his career working to change that. Two years ago, he was diagnosed with stage 4 lung cancer himself.
NPR's Yuki Noguchi featured his story this past Saturday on Weekend Edition: how precision therapies matched to a tumor's genetic profile have extended his life and kept his symptoms controlled, why genetic subtyping matters now that targeted drugs exist for roughly two-thirds of cases, and how much ground is left to cover. Five-year survival across all stages remains around 30%. Only 18% of high-risk people get screened.
Dr. Lin’s hope is that if lung cancer can't be cured, it can at least be managed like a chronic disease. He is equally clear about the barriers: therapies that cost hundreds of thousands of dollars, insurance hurdles even for a Stanford physician, and a screening toolkit that still depends almost entirely on low-dose CT.
We are grateful to him for sharing this so openly, and for continuing to teach, advocate, and push the field forward.